Ginkgo Bioworks Holdings (DNA) Gains from Investment Securities (2021 - 2024)

Ginkgo Bioworks Holdings (DNA) has reported Gains from Investment Securities for 4 consecutive years, with -$1.5 million the latest figure, recorded in Q3 2024.

• For the quarter ending Q3 2024, Gains from Investment Securities rose 19.2% year-over-year to -$1.5 million; the trailing twelve-month figure through Jun 2025 stood at -$1.5 million (up 87.89% YoY), and the FY2024 full-year result was -$5.7 million, down 10.31% from the prior year.
• Gains from Investment Securities rose to -$1.5 million in Q3 2024 per DNA's latest filing, from -$3.2 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $18.5 million in Q3 2021 and bottomed at -$85.0 million in Q1 2022.
• Historically, Gains from Investment Securities has averaged -$15.0 million across 4 years, with a median of -$1.9 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Gains from Investment Securities surged 119.07% in 2023, then sank 172.13% in 2024.
• Over 4 years, Gains from Investment Securities stood at -$77.1 million in 2021, then jumped by 62.55% to -$28.9 million in 2022, then jumped by 77.3% to -$6.6 million in 2023, then jumped by 76.69% to -$1.5 million in 2024.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$1.5 million, -$3.2 million, and -$940000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.